Former Chief Medical Officer · Travere Therapeutics, Inc. (TVTX)

Noah Rosenberg

A named executive officer of Travere Therapeutics in every fiscal year CompBrief holds from FY2018 to FY2021. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$2,780,608

Salary $507,766Stock awards $403,200

FY2020: $1,655,032

2nd of 6 named executive officers at Travere Therapeutics by FY2021 total.

6 named officers on file for Travere Therapeutics, FY2021

Noah Rosenberg’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 11 equity grants, each cited to its filing
  • TVTX’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Travere Therapeutics’s whole pay program stands against its peers

  • Travere Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on TVTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 4, 2022 (DEF 14A).

Free

Get Noah Rosenberg’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Noah Rosenberg compensation by year

Travere Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Travere Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021
Salary$183,622$432,083$447,002$507,766
Bonus$100,000$0$0$0
Stock awards$571,600$215,520$432,880$403,200
Option awards$1,183,611$453,000$508,217$791,194
Non-equity incentive$97,750$195,075$254,573$0
Pension and deferred compensation$0$0$0$0
All other$266,500$73,965$12,360$1,078,448
Total$2,403,083$1,369,643$1,655,032$2,780,608

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Travere Therapeutics, Inc. DEF 14A filed April 4, 2022, accession 0001438533-22-000014, and prior-year filings.

How this page was built: the Travere Therapeutics, Inc. filed document, accession 0001438533-22-000014. Every figure is read from that document and cited to the page and table it appears in. Filed April 4, 2022.

$2.4M
$1.4M
$1.7M
$2.8M
FY18
FY19
FY20
FY21
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
PSU7,500$232,800—
PSU5,000$155,200—
PSU2,250$69,840—
PSU1,500$46,560—
Option28,750—$26.88
Option3,334—$17.96
Option13,750—$15.46

Per the Outstanding Equity Awards at Fiscal Year-End table in Travere Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Travere Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Eric DubePresident, Chief Executive Officer and Director$5,739,010
Noah Rosenberg · this pageFormer Chief Medical Officer$2,780,608
William RoteSenior Vice President and Head of Research and Development$1,946,740
Laura ClagueSenior Vice President and Chief Financial Officer$1,934,671
Elizabeth ReedSenior Vice President, General Counsel and Corporate Secretary$1,891,071
Peter HeermaChief Commercial Officer$1,880,976

The full Travere Therapeutics compensation record

free company brief

This page is one person within Travere Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Travere Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Noah Rosenberg's compensation dossier · One-time report. No refunds.